Beretta-Piccoli C
Ospedale Italiano, Viganello, Switzerland.
Drugs. 1988;36 Suppl 1:35-43. doi: 10.2165/00003495-198800361-00007.
Ketanserin is a S2-serotonergic receptor antagonist with antihypertensive activity. 24 patients with diabetes mellitus and mild hypertension were studied with a double-blind, placebo-controlled protocol. Ketanserin given in doses up to 80 mg daily caused a slight decrease of supine and upright blood pressure. However, these pressures did not differ significantly from those observed in the placebo group. There were no significant changes in heart rate, bodyweight, plasma concentrations of glucose, C-peptide, glycosylated haemoglobin, plasma total cholesterol and triglycerides, their lipoprotein fractions and the responses of plasma glucose and immunoreactive insulin to an oral glucose loading test. In 8 hypertensive diabetics, ketanserin administered for 8 weeks did not modify plasma angiotensin II and noradrenaline concentrations or the pressor reactivity to phenylephrine, angiotensin II and noradrenaline. Thus, in diabetic patients with arterial hypertension, ketanserin has a weak antihypertensive effect, does not unfavourably influence glucose and lipid metabolism and does not modify sympathetic-dependent regulation.
酮色林是一种具有降压活性的S2 - 血清素能受体拮抗剂。采用双盲、安慰剂对照方案对24例糖尿病合并轻度高血压患者进行了研究。每日给予高达80毫克剂量的酮色林可使仰卧位和直立位血压略有下降。然而，这些血压与安慰剂组观察到的血压并无显著差异。心率、体重、血浆葡萄糖、C肽、糖化血红蛋白、血浆总胆固醇和甘油三酯浓度、它们的脂蛋白组分以及口服葡萄糖负荷试验中血浆葡萄糖和免疫反应性胰岛素的反应均无显著变化。在8例高血压糖尿病患者中，给予酮色林8周并未改变血浆血管紧张素II和去甲肾上腺素浓度，也未改变对去氧肾上腺素、血管紧张素II和去甲肾上腺素的升压反应性。因此，在患有动脉高血压的糖尿病患者中，酮色林具有较弱的降压作用，不会对葡萄糖和脂质代谢产生不利影响，也不会改变交感神经依赖性调节。
